Thyroid Cancer Survivorship: A Physician’s Own Experience Kaniksha Desai, MD, interviews Anupam Kotwal, MD, about…
Read More
From Clinical Thyroidology® for the Public: Once a cancer is diagnosed and surgery is an…
Given the evolving landscape of therapeutic options for RAIR-DTC, it is essential to highlight the importance of timely evaluating patients with advanced thyroid cancer.
Thyroid cancers (TC) are driven by a handful of genetic alterations. Papillary TC primarily harbors mutations involving BRAF, RAS or RET genes.
Medullary thyroid cancer (MTC) is a rare thyroid malignancy and considered a neuroendocrine type of tumor.
There are limited number of studies that have examined patients preferences concerning treatment options for patients with thyroid cancer.
Thyroid cancer in pediatric patients is not a rare entity, in fact it is the most common non-CNS solid tumor in childhood.
Familial non-medullary thyroid cancer (FNMTC) constitutes 3–9% of all thyroid cancer cases and is divided into syndromic and non-syndromic FNMTC.
After receiving a diagnosis of papillary thyroid cancer, intuitively, the thought has been that surgery is the next step. While this was the standard in the past, we now know that in specific situations immediate surgery may not be necessary.
Thyroid Journal Program Thyroid®, Clinical Thyroidology®, and VideoEndocrinology™ Latest Impact Factor: 5.309 Special Collection: Virtual Review…
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.